“Now we have chemotherapy-free immunotherapy options for patients whose myeloma has relapsed for the first time,” said senior ...

In " Beyond Diagnosis: Multiple Myeloma," Cleveland Clinic hematologist Sandra Mazzoni, DO, and host John Mangels continue ...

New BCMA-targeted bispecific antibody addresses critical unmet need in India, offering deep and durable responses for heavily ...

Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ...

"ASCO26: BMS and J&J debut shining multiple myeloma data" was originally created and published by Pharmaceutical Technology, ...

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in ...

Discover the top foods for multiple myeloma, including leafy greens, cold-water fish, berries, legumes, seeds, and whole ...

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, discusses the state of the pipeline in multiple myeloma.

Multiple myeloma – a rare form of blood cancer – is usually found in people 65 and older. While it’s rare in young adults, a small percentage of people 19-40 also have the disease. Only 10% of people ...

Multiple myeloma is a type of blood cancer that starts in your bone marrow. This is the soft, spongy tissue inside your bones that makes most of your blood cells. It includes plasma cells, which help ...